Lyrica Approved for Spinal Neuropathic Pain – What Are the MSA Implications if Pfizer Extends Patent?
Posted on July 3, 2012 by Tower MSA Partners
On June 21, 2012, the Food and Drug Administration announced its approval of Lyrica for use in the management of neuropathic pain associated with chronic, debilitating spinal cord injuries. Lyrica, the brand name for pregabalin, is manufactured by Pfizer (NYSE: PFE) and is…
For Media Inquires, Contact:
Helen King Patterson
Search our blog:
Contact Us for a FREE Consultation